Pancreatic Cancer Research

ResearcherAsan Medical CenterNo recent work listed

Jaewoo Kwon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8922-4374; OpenAlex author ID A5051616419. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2019: 3 papers · 2020: 5 papers · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers

Papers 16

  1. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1272↗
  2. Robotic versus laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: A propensity score-matched analysis. First author DOI 10.1016/j.hbpd.2022.06.001↗
  3. Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. Co-author DOI 10.3390/biomedicines10061341↗
  4. A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis. Co-author DOI 10.1002/jhbp.853↗
  5. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-80383-1↗
  6. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  7. Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadren… Co-author DOI 10.3390/biomedicines9101291↗
  8. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i11.1423↗
  9. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Co-author DOI 10.1038/s41598-020-68703-x↗
  10. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients. Co-author DOI 10.1097/md.0000000000022115↗
  11. Comparison of Minimally Invasive Versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis. Co-author DOI 10.3390/cancers12040982↗
  12. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  13. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9061953↗
  14. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/bjs.11144↗
  15. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. First author DOI 10.1002/jhbp.627↗
  16. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13206↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ki Byung Song · 15 shared papers, 2019–2023 · strength 1.78
  2. Dae Wook Hwang · 15 shared papers, 2019–2023 · strength 1.78
  3. Song Cheol Kim · 13 shared papers, 2019–2023 · strength 1.56
  4. Yejong Park · 12 shared papers, 2019–2023 · strength 1.40
  5. Woohyung Lee · 11 shared papers, 2020–2023 · strength 1.30
  6. Eunsung Jun · 7 shared papers, 2020–2021 · strength 0.82
  7. Sarang Hong · 5 shared papers, 2019–2021 · strength 0.50
  8. Dakyum Shin · 4 shared papers, 2020–2023 · strength 0.50
  9. Sang Hyun Shin · 4 shared papers, 2019–2022 · strength 0.44
  10. Changhoon Yoo · 3 shared papers, 2019–2021 · strength 0.30
  11. Daegwang Yoo · 3 shared papers, 2019–2020 · strength 0.28
  12. Kyu‐pyo Kim · 2 shared papers, 2020–2021 · strength 0.21
  13. Baek‐Yeol Ryoo · 2 shared papers, 2020–2021 · strength 0.21
  14. Sung Ryol Lee · 1 shared paper, 2023 · strength 0.19
  15. So Jeong Yoon · 1 shared paper, 2022 · strength 0.16
  16. Jin Seok Heo · 1 shared paper, 2022 · strength 0.16
  17. In Woong Han · 1 shared paper, 2022 · strength 0.16
  18. Chang-Sup Lim · 1 shared paper, 2022 · strength 0.16
  19. Woohyun Jung · 1 shared paper, 2022 · strength 0.16
  20. Song Cheol Kim · 1 shared paper, 2021 · strength 0.12
  21. Min Kyu Sung · 1 shared paper, 2021 · strength 0.11
  22. Naru Kim · 1 shared paper, 2021 · strength 0.11
  23. Ji Sun Lee · 1 shared paper, 2020 · strength 0.10
  24. Robert M. Hoffman · 1 shared paper, 2020 · strength 0.10
  25. Song Cheol Kim · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.